Axsome Therapeutics to Present at Biotech Showcase 2019
18 déc. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update
09 nov. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
Final Phase 3 results of AXS-05 in treatment resistant depression now anticipated in 1Q 2019 Final Phase 2 results of AXS-05 in major depressive disorder anticipated around year-end 2018 Phase 2/3...
Axsome Therapeutics to Report Third Quarter 2018 Financial Results on November 9, 2018
01 nov. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Friday, November 9, 2018 at 8:00 AM Eastern Time NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage...
Axsome Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update
08 août 2018 07h00 HE
|
Axsome Therapeutics, Inc.
Interim analysis results from two Phase 3 trials and topline results from one Phase 2 trial of AXS-05 anticipated in 4Q 2018 Phase 3 trial of AXS-07 in acute migraine anticipated to start in 4Q 2018 ...
Axsome Therapeutics to Report Second Quarter 2018 Financial Results on August 8, 2018
01 août 2018 07h00 HE
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Wednesday, August 8, 2018 at 8:00 AM Eastern Time NEW YORK, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update
08 mai 2018 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, May 08, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system...
Axsome Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018
01 mai 2018 07h00 HE
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Tuesday, May 8, 2018 at 8:00 AM Eastern Time NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage...
Axsome Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
07 mars 2018 07h00 HE
|
Axsome Therapeutics, Inc.
Interim analyses of STRIDE-1 and ADVANCE-1 trials of AXS-05 anticipated in 2018 Company to host conference call today at 8:00 AM Eastern NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Axsome...
Axsome Therapeutics to Present at 2018 BIO CEO & Investor Conference
05 févr. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 Trial
09 janv. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
COAST-1 is a Phase 3 trial of AXS-02 in knee osteoarthritis associated with bone marrow lesions CREATE-1 is a Phase 3 trial of AXS-02 in complex regional pain syndrome Significant reduction in bone...